Generic Oncology Drugs Market Size & Industry Analysis By 2027

Generic Oncology Drugs Market to 2027 - Global Analysis and Forecasts by Molecular Type (Large Molecule, Small Molecule); Indication (Lung Cancer, Stomach Cancer, Colorectal Cancer, Breast Cancer, Prostate Cancer, Liver Cancer, Kidney Cancer, Cervical Cancer, Others), and Geography

  • Report Code : TIPRE00006393
  • Category : Pharmaceuticals
  • Status : Published
  • No. of Pages : 152
Buy Now

The Generic Oncology Drugs Market was valued at US$ 21,200.00 million in 2018 and it is projected to reach US$ 36,029.60 million by 2027; it is expected to grow at a CAGR of 6.3% from 2019 to 2027.

Generic Oncology Drugs in healthcare is the use of machine-learning algorithms and software to analyze, process and present complex medical and health care data. It has been widely used to support clinical decisions, improve workflows and predict health outcomes. Thus, wide application of AI in the healthcare sector is likely to propel the growth of the market. The growth of the Generic Oncology Drugs Market is attributed to the increasing prevalence of cancer across the globe, growing generic drug launches and benefits offered by the generic drugs are likely to boost the market growth, whereas, inclination towards the personalized medicine for cancer is likely to be a prevalent trend in the future years.

The Generic Oncology Drugs Market is expected to witness substantial growth post-pandemic. The COVID-19 has affected economies and industries in various countries due to lockdowns, travel bans, and business shutdowns. The COVID-19 crisis has overburdened public health systems in many countries and highlighted the strong need for sustainable investment in health systems. As the COVID-19 pandemic progresses, the healthcare industry is expected to see a drop in growth. The life sciences segment thrives due to increased demand for invitro diagnostic products and rising research and development activities worldwide. However, the medical technologies and imaging segment is witnessing drop in sales due to a smaller number of surgeries being carried out and delayed or prolonged equipment procurement. Additionally, virtual consultations by healthcare professionals are expected to become the mainstream care delivery model post-pandemic. With telehealth transforming care delivery, digital health will continue to thrive in coming years. In addition, disrupted clinical trials and the subsequent delay in drug launches is also expected to pave the way for entirely virtual trials in the future. New technologies such as mRNA is expected to emerge and shift the pharmaceutical industry and market is also expected to witness more vertical integration and joint ventures in coming years.

Lucrative Regions for Generic Oncology Drugs Market



Lucrative Regions for Generic Oncology Drugs in Healthcare Market
  • Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
  • Request discounts available for Start-Ups & Universities

Market Insights

Growing Applications of Generic Oncology Drugs in Healthcare to Drive Generic Oncology Drugs Market Growth

Cancer is one of the leading cause of deaths across the globe and is extremely affecting the quality of life. Thus, cancer will be burden on society if not diagnosed and treated on time. According to the World Health Organization in 2018, approximately, 9.6 million deaths across the globe were due to cancer. Furthermore, the National Cancer Institute predicted that in 2018, approximately 1,735,350 new cancer cases will be diagnosed in the US.

Additionally, cancer is found to be common in European countries as well. As per the Cancer Research UK, in 2016, around 163,444 deaths in UK were due to cancer. 

Furthermore, Asia Pacific region is also facing the problem of growing prevalence of cancer. The top 15 countries with

Cancer prevalence are: Japan, Taiwan, Singapore, South Korea, Malaysia, Thailand, China, Philippines, Sri Lanka, Vietnam, Indonesia, Mongolia, India, Laos, and Cambodia. According to the National Institute of Cancer Prevention and Research (NICPR), in 2018, in India total deaths due to cancer were 784,821.

These statistics determine an increase in the demand for advanced cancer diagnostics in various regions across the globe. Thus driving the growth of generic oncology drugs during the forecast period.

The market for generic cancer drugs is driven by frequent drug launches. Most of the major market players are involved in the manufacturing wide range of generic cancer drugs that help in reducing cost of cancer care. For instance, in July 2019, Lupin Pharmaceuticals, Inc. launched a generic Imatinib Mesylate tablets used to treat certain types of cancer.

Additionally April 2019, Emcure Pharmaceuticals, a leading pharmaceutical company from India launched world’s first generic Eribulin for treatment of metastatic breast cancer. 

Emcure is marketing the drug with brand name ‘Eribilin’, that offers high-quality and cost-effective treatment option to breast cancer patients in India. The medicine Eribilin is Eisai pharmaceutical’s generic version of expired patent product. 

Moreover, in January 2019, Hetero Healthcare Ltd launched a new generic Lapatinib tablets, which are used to treat metastatic breast cancer in India. The tablets are consumed along with Capecitabine or Letrozole, that together, inhibit the growth of cancer cells in patients. Thus, the constant developments in generic oncology drugs accelerate the market growth during the forecast period.

Generic drugs are copies of branded drugs. Their pharmacological effects are similar to the branded counterparts.

Generic drugs are cost effective as the manufacturers have not invested in the development and marketing a new drug.

When a drug patent expires, other manufacturers apply for FDA approval in order to manufacture and sell the product. Hence generic drugs are cheaper than branded drugs. The generic drug has exactly the same effects, dosage, side effects, route of administration, safety, risks, and strength as the original branded drug. 

Generic drugs are important in oncology as some anticancer drugs are only offered as generics. In most of the cases like, children with acute lymphoblastic leukemia or women patients with early-stage breast cancer are treated with generics. Generic drugs are extensively used in supportive care. The most significant benefit of using generic drugs is the cost, which is up to 85% less than that of a branded drug.


Molecular Type-Based Insights

In terms of molecular type, the Generic Oncology Drugs Market is segmented into large molecule, small molecule. In 2018, the small molecule segment held a largest market share of 87.67% of the generic oncology drugs market, by molecule type.

Generic Oncology Drugs Market, by Molecular Type – 2018 and 2027



Generic Oncology Drugs in Healthcare Market, by Molecular Type – 2018 and 2027
  • Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
  • Request discounts available for Start-Ups & Universities

Indication-Based Insights

Based on indication, the Generic Oncology Drugs Market is segmented into lung cancer, stomach cancer, colorectal cancer, breast cancer, prostate cancer, liver cancer, kidney cancer, cervical cancer, others. In 2018, the lung cancer segment held the largest share of the market, by indication.

Customize Research To Suit Your Requirement

We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.

Generic Oncology Drugs Market: Strategic Insights

generic-oncology-drugs-market
Market Size Value inUS$ 21,200.00 Million in 2018
Market Size Value byUS$ 36,029.60 Million by 2027
Growth rateCAGR of 6.3% from 2019-2027
Forecast Period2019-2027
Base Year2019
Analyst Image

Akshay

Have a question?

Akshay will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.

Analyst Image  Speak to Analyst

The Generic Oncology Drugs Market players are adopting the product launch and expansion strategies to cater to changing customer demands worldwide, which also allows them to maintain their brand name globally.

Generic Oncology Drugs Market – by Molecular Type

  • Large Molecule
  • Small Molecule

Generic Oncology Drugs Market – by Indication

  • Lung Cancer
  • Stomach Cancer
  • Colorectal Cancer
  • Breast Cancer
  • Prostate Cancer
  • Liver Cancer
  • Kidney Cancer
  • Cervical Cancer
  • Others

Generic Oncology Drugs Market – by Geography

  • North America

    • US
    • Canada
    • Mexico
  • Europe

    • France
    • Germany
    • Italy
    • UK
    • Spain
    • Rest of Europe
  • Asia Pacific (APAC)

    • China
    • India
    • South Korea
    • Japan
    • Australia
    • Rest of APAC
  • Middle East & Africa (MEA)

    • South Africa
    • Saudi Arabia
    • UAE
    • Rest of MEA
  • South America and Central America (SCAM)

    • Brazil
    • Argentina
    • Rest of SCAM

Company Profiles

  • Teva Pharmaceutical Industries LTD.
  • Sandoz International GMBH
  • Glenmark Pharmaceuticals LIMITED
  • Sun Pharmaceutical Industries LTD
  • MSN Laboratories
  • Aurobindo Pharma
  • Intas Pharmaceuticals LTD
  • Zydus Cadila
  • Mylan N.V.
  • Shilpa Medicare LTD
  • Fresenius Kabi AG
  • Dr. Reddy’s Laboratories.
Report Coverage
Report Coverage

Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends

Segment Covered
Segment Covered

Molecular Type ; Indication , and Geography

Regional Scope
Regional Scope

North America, Europe, Asia Pacific, Middle East & Africa, South & Central America

Country Scope
Country Scope

US, Canada, Mexico, UK, Germany, Spain, Italy, France, India, China, Japan, South Korea, Australia, UAE, Saudi Arabia, South Africa, Brazil, Argentina

1. Introduction

1.1 Scope of the Study

1.2 The Insight Partners Research Report Guidance

1.3 Market Segmentation

1.3.1 Global Generic Oncology Drugs Market – By Molecule Type

1.3.2 Global Generic Oncology Drugs Market – By Application

1.3.3 Global Generic Oncology Drugs Market – By Geography

2. Global Generic Oncology Drugs Market – Key Takeaways

3. Research Methodology

3.1 Coverage

3.2 Secondary Research

3.3 Primary Research

4. Global Generic Oncology Drugs– Market Landscape

4.1 Overview

4.2 PEST Analysis

4.2.1 North America PEST Analysis

4.2.2 Europe PEST Analysis

4.2.3 Asia Pacific – PEST Analysis

4.2.4 Middle East & Africa– PEST Analysis

4.2.5 South & Central America – PEST Analysis

4.3 Expert Opinions

5. Global Generic Oncology Drugs Market – Key Industry Dynamics

5.1 Key Market Drivers

5.1.1 Growing Cancer Prevalence Across The Globe

5.1.2 New Drug Launches

5.1.3 Benefits Offered By Generic Drugs

5.2 Key Market Restraints

5.2.1 Pricing Pressure

5.3 Key Market Opportunities

5.3.1 Growing Pharmaceutical Industry in Emerging Economies

5.4 Future Trends

5.4.1 Inclination Towards Personalized Medicine

5.5 Impact Analysis

6. Generic Oncology Drugs Market – Global Analysis

6.1 Global Generic Oncology Drugs Market Revenue Forecasts And Analysis

6.2 Global Generic Oncology Drugs Market, By Geography - Forecasts And Analysis

6.3 Market Positioning of Key Players

7. Generic Oncology Drugs Market Analysis And Forecasts To 2027 – Molecule Type

7.1 Overview

7.2 Global Generic Oncology Drugs Market Share by Molecule Type 2018 & 2027 (%)

7.3 Large Molecules Market

7.3.1 Overview

7.3.2 Large Molecules Market Revenue and Forecast to 2027 (US$ Mn)

7.4 Small Molecules Market

7.4.1 Overview

7.4.2 Small Molecules Market Revenue and Forecast to 2027 (US$ Mn)

8. Generic Oncology Drugs Market Analysis And Forecasts To 2027 – Indication

8.1 Overview

8.2 Global Generic Oncology Drugs Market Share by Indication 2018 & 2027 (%)

8.3 Lung Cancer

8.3.1 Overview

8.3.2 Lung Cancer Market Revenue and Forecast to 2027 (US$ Mn)

8.4 Stomach Cancer

8.4.1 Overview

8.4.2 Stomach Cancer Market Revenue and Forecast to 2027 (US$ Mn)

8.5 Colorectal Cancer

8.5.1 Overview

8.5.2 Colorectal Cancer Market Revenue and Forecast to 2027 (US$ Mn)

8.6 Breast Cancer

8.6.1 Overview

8.6.2 Breast Cancer Market Revenue and Forecast to 2027 (US$ Mn)

8.7 Prostate Cancer

8.7.1 Overview

8.7.2 Prostate Cancer Market Revenue and Forecast to 2027 (US$ Mn)

8.8 Liver Cancer

8.8.1 Overview

8.8.2 Liver Cancer Market Revenue and Forecast to 2027 (US$ Mn)

8.9 Kidney Cancer

8.9.1 Overview

8.9.2 Kidney Cancer Market Revenue and Forecast to 2027 (US$ Mn)

8.10 Cervical Cancer

8.10.1 Overview

8.10.2 Cervical Cancer Market Revenue and Forecast to 2027 (US$ Mn)

8.11 Others

8.11.1 Overview

8.11.2 Others Market Revenue and Forecast to 2027 (US$ Mn)

9. Generic Oncology Drugs Market Revenue and Forecasts to 2027 – Geographical Analysis

9.1 North America Generic Oncology Drugs Market Revenue And Forecasts To 2027

9.1.1 North America Generic Oncology Drugs market Revenue and Forecasts to 2027 (US$ Mn)

9.2 North America Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Molecule Type (US$ Mn)

9.3 North America Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Indication (US$ Mn)

9.3.1 North America Generic Oncology Drugs Market Revenue and Forecasts to 2027, By Country (%)

9.3.2 US Generic Oncology Drugs Market Revenue and Forecasts to 2027 (US$ Mn)

9.3.2.1 US Generic Oncology Drugs Market Revenue and Forecasts to 2027 (US$ Mn)

9.3.2.2 US Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Molecule Type (US$ Mn)

9.3.2.3 US Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Indication (US$ Mn)

9.3.3 Canada Generic Oncology Drugs Market Revenue and Forecasts to 2027 (US$ Mn)

9.3.3.1 Canada Generic Oncology Drugs Market Revenue and Forecasts to 2027 (US$ Mn)

9.3.4 Canada Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Molecule Type (US$ Mn)

9.3.5 Canada Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Indication (US$ Mn)

9.3.6 Mexico Generic Oncology Drugs Market Revenue and Forecasts to 2027 (US$ Mn)

9.3.6.1 Mexico Generic Oncology Drugs Market Revenue and Forecasts to 2027 (US$ Mn)

9.3.7 Mexico Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Molecule Type (US$ Mn)

9.3.8 Mexico Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Indication (US$ Mn)

9.4 Europe Generic Oncology Drugs Market Revenue And Forecasts To 2027

9.4.1 Europe Generic Oncology Drugs Market Revenue and Forecasts to 2027 (US$ Mn)

9.5 Europe Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Molecule Type (US$ Mn)

9.6 Europe Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Indication (US$ Mn)

9.6.1 Europe Generic Oncology Drugs Market Revenue and Forecasts to 2027, By Country (%)

9.6.2 UK Generic Oncology Drugs Market Revenue and Forecasts to 2027 (US$ Mn)

9.6.2.1 UK Generic Oncology Drugs Market Revenue and Forecasts to 2027 (US$ Mn)

9.6.3 UK Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Molecule Type (US$ Mn)

9.6.4 UK Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Indication (US$ Mn)

9.6.5 Germany Generic Oncology Drugs Market Revenue and Forecasts to 2027 (US$ Mn)

9.6.5.1 Germany Generic Oncology Drugs Market Revenue and Forecasts to 2027 (US$ Mn)

9.6.6 Germany Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Molecule Type (US$ Mn)

9.6.7 Germany Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Indication (US$ Mn)

9.6.8 France Generic Oncology Drugs Market Revenue and Forecasts to 2027 (US$ Mn)

9.6.8.1 France Generic Oncology Drugs Market Revenue and Forecasts to 2027 (US$ Mn)

9.6.9 France Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Molecule Type (US$ Mn)

9.6.10 France Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Indication (US$ Mn)

9.6.11 Italy Generic oncology drugs market Revenue and Forecasts to 2027 (US$ Mn)

9.6.11.1 Italy Generic Oncology Drugs Market Revenue and Forecasts to 2027 (US$ Mn)

9.6.12 Italy Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Molecule Type (US$ Mn)

9.6.13 Italy Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Indication (US$ Mn)

9.6.14 Spain Generic Oncology Drugs Market Revenue and Forecasts to 2027 (US$ Mn)

9.6.14.1 Spain Generic Oncology Drugs Market Revenue and Forecasts to 2027 (US$ Mn)

9.6.15 Spain Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Molecule Type (US$ Mn)

9.6.16 Spain Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Indication (US$ Mn)

10. Asia Pacific Generic Oncology Drugs Market Revenue and Forecasts to 2027

10.1 Overview

10.2 Asia Pacific Generic Oncology Drugs Market Revenue and Forecasts to 2027 (US$ Mn)

10.3 Asia Pacific Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Molecule Type (US$ Mn)

10.4 Asia Pacific Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Indication (US$ Mn)

10.5 Asia Pacific Generic Oncology Drugs Market Revenue and Forecasts to 2027, By Country (%)

10.6 Japan Generic Oncology Drugs Market Revenue and Forecasts to 2027 (US$ Mn)

10.6.1 Japan Generic Oncology Drugs Market Revenue and Forecasts to 2027 (US$ Mn)

10.6.2 Japan Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Molecule Type (US$ Mn)

10.6.3 Japan Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Indication (US$ Mn)

10.7 China Generic Oncology Drugs Market Revenue and Forecasts to 2027 (US$ Mn)

10.7.1 China Generic Oncology Drugs Market Revenue and Forecasts to 2027 (US$ Mn)

10.7.2 South Africa Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Molecule Type (US$ Mn)

10.7.3 China Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Indication (US$ Mn)

10.8 India Generic Oncology Drugs Market Revenue and Forecasts to 2027 (US$ Mn)

10.8.1 India Generic Oncology Drugs Market Revenue and Forecasts to 2027 (US$ Mn)

10.8.2 India Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Molecule Type (US$ Mn)

10.8.3 India Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Indication (US$ Mn)

10.9 Australia Generic Oncology Drugs Market Revenue and Forecasts to 2027 (US$ Mn)

10.9.1 Australia Generic Oncology Drugs Market Revenue and Forecasts to 2027 (US$ Mn)

10.9.2 Australia Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Molecule Type (US$ Mn)

10.9.3 Australia Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Indication (US$ Mn)

10.10 South Korea Generic Oncology Drugs Market Revenue and Forecasts to 2027 (US$ Mn)

10.10.1 South Korea Generic Oncology Drugs Market Revenue and Forecasts to 2027 (US$ Mn)

10.10.2 South Korea Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Molecule Type (US$ Mn)

10.10.3 South Korea Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Indication (US$ Mn)

11. Middle East & Africa Generic Oncology Drugs Market Revenue and Forecasts to 2027

11.1 Overview

11.2 Middle East & Africa Generic Oncology Drugs Market Revenue and Forecasts to 2027 (US$ Mn)

11.3 Middle East & Africa Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Molecule Type (US$ Mn)

11.4 Middle East & Africa Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Indication (US$ Mn)

11.5 Middle East & Africa Generic Oncology Drugs Market Revenue and Forecasts to 2027, By Country (%)

11.6 South Africa Generic Oncology Drugs Market Revenue and Forecasts to 2027 (US$ Mn)

11.6.1 South Africa Generic Oncology Drugs Market Revenue and Forecasts to 2027 (US$ Mn)

11.6.2 South Africa Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Molecule Type (US$ Mn)

11.6.3 South Africa Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Indication (US$ Mn)

11.7 Saudi Arabia Generic Oncology Drugs Market Revenue and Forecasts to 2027 (US$ Mn)

11.7.1 Saudi Arabia Generic Oncology Drugs Market Revenue and Forecasts to 2027 (US$ Mn)

11.7.2 Saudi Arabia Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Molecule Type (US$ Mn)

11.7.3 Saudi Arabia Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Indication (US$ Mn)

11.8 UAE Generic Oncology Drugs Market Revenue and Forecasts to 2027 (US$ Mn)

11.8.1 UAE Generic Oncology Drugs Market Revenue and Forecasts to 2027 (US$ Mn)

11.8.2 UAE Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Molecule Type (US$ Mn)

11.8.3 UAE Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Indication (US$ Mn)

12. South and Central America Generic Oncology Drugs Market Revenue and Forecasts to 2027

12.1 Overview

12.2 South and Central America Generic Oncology Drugs Market Revenue and Forecasts to 2027 (US$ Mn)

12.3 South and Central America Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Molecule Type (US$ Mn)

12.4 South and Central America Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Indication (US$ Mn)

12.5 South and Central America Generic Oncology Drugs Market Revenue and Forecasts to 2027, By Country (%)

12.6 Brazil Generic Oncology Drugs Market Revenue and Forecasts to 2027 (US$ Mn)

12.6.1.1 Brazil Generic Oncology Drugs Market Revenue and Forecasts to 2027 (US$ Mn)

12.6.2 Brazil Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Molecule Type (US$ Mn)

12.6.3 Brazil Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Indication (US$ Mn)

12.6.4 Argentina Generic Oncology Drugs Market

12.6.4.1 Argentina Generic Oncology Drugs Market Revenue and Forecasts to 2027 (US$ Mn)

12.6.5 Argentina Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Molecule Type (US$ Mn)

12.6.6 Argentina Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Indication (US$ Mn)

13. Generic Oncology Drugs Market – Industry Landscape

13.1 Overview

13.2 Growth Strategies in the Generic Oncology Drugs Market, 2016-2019

13.3 Organic Growth Strategies

13.4 Inorganic Growth Strategies

14. Generic Oncology Drugs Market–Key Company Profiles

14.1 Dr. Reddy’s Laboratories Ltd

14.1.1 Key Facts

14.1.2 Business Description

14.1.3 Financial Overview

14.1.4 Product Portfolio

14.1.5 SWOT Analysis

14.1.6 Key Developments

14.2 Fresenius Kabi AG

14.2.1 Key Facts

14.2.2 Business Description

14.2.3 Financial Overview

14.2.4 Product Portfolio

14.2.5 SWOT Analysis

14.2.6 Key Developments

14.3 Cipla Inc.

14.3.1 Key Facts

14.3.2 Business Description

14.3.3 Financial Overview

14.3.4 Product Portfolio

14.3.5 SWOT Analysis

14.3.6 Key Developments

14.4 Mylan N.V.

14.4.1 Key Facts

14.4.2 Business Description

14.4.3 Financial Overview

14.4.4 Product Portfolio

14.4.5 SWOT Analysis

14.4.6 Key Developments

14.5 Zydus Cadila

14.5.1 Key Facts

14.5.2 Business Description

14.5.3 Financial Overview

14.5.4 Product portfolio

14.5.5 SWOT Analysis

14.5.6 KEY DEVELOPMENTS

14.6 Intas Pharmaceuticals

14.6.1 Key Facts

14.6.2 Business Description

14.6.3 Financial Information

14.6.4 Product Portfolio

14.6.5 SWOT Analysis

14.6.6 Key Developments

14.7 Aurobindo Pharma

14.7.1 Key Facts

14.7.2 Business Description

14.7.3 Financial Overview

14.7.4 Product Portfolio

14.7.5 SWOT Analysis

14.7.6 Key Developments

14.8 Teva Pharmaceutical Industries Ltd.

14.8.1 Key Facts

14.8.2 Business Description

14.8.3 Financial Overview

14.8.4 Product Portfolio

14.8.5 SWOT Analysis

14.8.6 Key Developments

14.9 Sandoz International GmbH (A Division of Novartis AG)

14.9.1 Key Facts

14.9.2 Business Description

14.9.3 Financial Overview

14.9.4 Product Portfolio

14.9.5 SWOT Analysis

14.9.6 Key Developments

14.10 Glenmark

14.10.1 Key Facts

14.10.2 Business Description

14.10.3 Financial Overview

14.10.4 Product Portfolio

14.10.5 SWOT Analysis

14.10.6 Key Developments

14.11 Sun Pharmaceutical Industries Ltd.

14.11.1 Key Facts

14.11.2 Business Description

14.11.3 Financial Overview

14.11.4 Product Portfolio

14.11.5 SWOT Analysis

14.11.6 Key Developments

14.12 MSN Laboratories

14.12.1 Key Facts

14.12.2 Business Description

14.12.3 Financial Overview

14.12.4 Product Portfolio

14.12.5 SWOT Analysis

14.12.6 Key Developments

15. Appendix

15.1 About The Insight Partners

15.2 Glossary Of Terms

LIST OF TABLES

Table 1. North America Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Molecule Type (US$ Mn)

Table 2. North America Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Indication (US$ Mn)

Table 3. US Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Molecule Type (US$ Mn)

Table 4. US Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Indication (US$ Mn)

Table 5. Canada Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Molecule Type (US$ Mn)

Table 6. Canada Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Indication (US$ Mn)

Table 7. Mexico Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Molecule Type (US$ Mn)

Table 8. Mexico Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Indication (US$ Mn)

Table 9. Europe Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Molecule Type (US$ Mn)

Table 10. Europe Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Indication (US$ Mn)

Table 11. UK Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Molecule Type (US$ Mn)

Table 12. UK Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Indication (US$ Mn)

Table 13. Germany Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Molecule Type (US$ Mn)

Table 14. Germany Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Indication (US$ Mn)

Table 15. France Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Molecule Type (US$ Mn)

Table 16. France Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Indication (US$ Mn)

Table 17. Italy Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Molecule Type (US$ Mn)

Table 18. Italy Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Indication (US$ Mn)

Table 19. Spain Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Molecule Type (US$ Mn)

Table 20. Spain Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Indication (US$ Mn)

Table 21. Asia Pacific Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Molecule Type (US$ Mn)

Table 22. Asia Pacific Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Indication (US$ Mn)

Table 23. Japan Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Molecule Type (US$ Mn)

Table 24. Japan Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Indication (US$ Mn)

Table 25. China Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Molecule Type (US$ Mn)

Table 26. China Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Indication (US$ Mn)

Table 27. India Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Molecule Type (US$ Mn)

Table 28. India Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Indication (US$ Mn)

Table 29. Australia Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Molecule Type (US$ Mn)

Table 30. Australia Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Indication (US$ Mn)

Table 31. South Korea Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Molecule Type (US$ Mn)

Table 32. South Korea Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Indication (US$ Mn)

Table 33. Middle East & Africa Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Molecule Type (US$ Mn)

Table 34. Middle East & Africa Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Indication (US$ Mn)

Table 35. South Africa Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Molecule Type (US$ Mn)

Table 36. South Africa Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Indication (US$ Mn)

Table 37. Saudi Arabia Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Molecule Type (US$ Mn)

Table 38. Saudi Arabia Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Indication (US$ Mn)

Table 39. UAE Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Molecule Type (US$ Mn)

Table 40. UAE Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Indication (US$ Mn)

Table 41. South and Central America Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Molecule Type (US$ Mn)

Table 42. South and Central America Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Indication (US$ Mn)

Table 43. Brazil Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Molecule Type (US$ Mn)

Table 44. Brazil Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Indication (US$ Mn)

Table 45. Argentina Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Molecule Type (US$ Mn)

Table 46. Argentina Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Indication (US$ Mn)

Table 47. Glossary Of Terms, Generic Oncology Drugs Market

LIST OF FIGURES

Figure 1. Generic Oncology Drugs Market Segmentation

Figure 2. Generic Oncology Drugs Segmentation, By Region

Figure 3. Asia Pacific Generic Oncology Drugs Market, Revenue (US$ Mn), 2018 & 2027

Figure 4. Global Generic Oncology Drugs Market By Product, Market Share (%), 2018

Figure 5. Global Generic Oncology Drugs Market By Indication, Market Share (%), 2018

Figure 6. North America : PEST Analysis

Figure 7. Europe: PEST Analysis

Figure 8. Asia Pacific PEST Analysis

Figure 9. Middle East & Africa PEST Analysis

Figure 10. South & Central America PEST Analysis

Figure 11. Most Prevalent Forms of Cancers Globally, 2018

Figure 12. Comparison of Brand – Name Drugs and Generic Drugs

Figure 13. Generic Oncology Drugs Market Impact Analysis of Driver And Restraints

Figure 14. Global Generic Oncology Drugs Market – Revenue Forecasts And Analysis – 2018- 2027

Figure 15. Global Generic Oncology Drugs Market – By Geography Forecasts And Analysis – 2018- 2027

Figure 16. Global Generic Oncology Drugs Market – Market Positioning

Figure 17. Global Generic Oncology Drugs Market Share by Molecule Type 2018 & 2027 (%)

Figure 18. Large Molecules Market Revenue And Forecasts To 2027 (US$ Mn)

Figure 19. Small Molecules Market Revenue And Forecasts To 2027 (US$ Mn)

Figure 20. Global Generic Oncology Drugs Market Share by Indication 2018 & 2027 (%)

Figure 21. Lung Cancer Market Revenue And Forecasts To 2027 (US$ Mn)

Figure 22. Stomach Cancer Market Revenue And Forecasts To 2027 (US$ Mn)

Figure 23. Colorectal Cancer Market Revenue And Forecasts To 2027 (US$ Mn)

Figure 24. Breast Cancer Market Revenue And Forecasts To 2027 (US$ Mn)

Figure 25. Prostate Cancer Market Revenue And Forecasts To 2027 (US$ Mn)

Figure 26. Liver Cancer Market Revenue And Forecasts To 2027 (US$ Mn)

Figure 27. Kidney Cancer Market Revenue And Forecasts To 2027 (US$ Mn)

Figure 28. Cervical Cancer Market Revenue And Forecasts To 2027 (US$ Mn)

Figure 29. Others Market Revenue And Forecasts To 2027 (US$ Mn)

Figure 30. North America Generic Oncology Drugs Market Revenue Overview, by Country, 2018 (US$ Mn)

Figure 31. North America Generic Oncology Drugs Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 32. North America Generic Oncology Drugs Market Revenue and Forecasts to 2027, By Country (%)

Figure 33. US Generic Oncology Drugs Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 34. Canada Generic Oncology Drugs Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 35. Mexico Generic Oncology Drugs Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 36. Europe Generic Oncology Drugs Market Revenue Overview, by Country, 2018 (US$ MN)

Figure 37. Europe Generic Oncology Drugs Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 38. Europe Generic Oncology Drugs Market Revenue and Forecasts to 2027, By Country (%)

Figure 39. UK Generic Oncology Drugs Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 40. Germany Generic Oncology Drugs Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 41. France Generic Oncology Drugs Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 42. Italy Generic Oncology Drugs Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 43. Spain Generic Oncology Drugs Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 44. Asia Pacific Generic Oncology Drugs Market Overview, by Country (2017)

Figure 45. Asia Pacific Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 46. Asia Pacific Generic Oncology Drugs Market Revenue and Forecasts to 2027, By Country (%)

Figure 47. Japan Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 48. China Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 49. India Oncology Drugs Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 50. Australia Generic Oncology Drugs Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 51. South Korea Generic Oncology Drugs Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 52. Middle East & Africa Generic Oncology Drugs Market Overview, by Country (2017)

Figure 53. Middle East & Africa Generic Oncology Drugs Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 54. Middle East & Africa Generic Oncology Drugs Market Revenue and Forecasts to 2027, By Country (%)

Figure 55. South Africa Generic Oncology Drugs Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 56. Saudi Arabia Generic Oncology Drugs Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 57. UAE Generic Oncology Drugs Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 58. South and Central America Generic Oncology Drugs Market Overview, by Country (2017)

Figure 59. South and Central America Generic Oncology Drugs Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 60. South and Central America Generic Oncology Drugs Market Revenue and Forecasts to 2027, By Country (%)

Figure 61. Brazil Generic Oncology Drugs Market Revenue And Forecasts To 2027 (US$ Mn)

Figure 62. Argentina Generic Oncology Drugs Market Revenue And Forecasts To 2027 (US$ Mn)

Figure 63. Growth Strategies in the Generic Oncology Drugs Market, 2016-2019

The List of Companies - Generic Oncology Drugs Market

  1. Teva Pharmaceutical Industries Ltd.
  2. Sandoz International GMBH
  3. Glenmark
  4. Sun Pharmaceutical Industries Ltd
  5. MSN Laboratories
  6. Aurobindo Pharma
  7. Intas Pharmaceuticals
  8. Zydus Cadila
  9. Mylan N.V.
  10. Cipla Inc.
  11. Fresenius Kabi AG
  12. Dr. Reddy’s Laboratories Ltd.

The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.

  1. Data Collection and Secondary Research:

As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.

Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.

  1. Primary Research:

The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.

For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.

A typical research interview fulfils the following functions:

  • Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
  • Validates and strengthens in-house secondary research findings
  • Develops the analysis team’s expertise and market understanding

Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:

  • Industry participants: VPs, business development managers, market intelligence managers and national sales managers
  • Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.

Below is the breakup of our primary respondents by company, designation, and region:

Research Methodology

Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.

  1. Data Analysis:

Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.

  • 3.1 Macro-Economic Factor Analysis:

We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.

  • 3.2 Country Level Data:

Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.

  • 3.3 Company Profile:

The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.

  • 3.4 Developing Base Number:

Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.

  1. Data Triangulation and Final Review:

The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.

We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.

We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.

Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Trends and growth analysis reports related to Generic Oncology Drugs Market